|
PRKACA expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 7.05030478442836E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
6.59529986180019E-10 |
| Normal-vs-Stage2 |
6.63400000044945E-07 |
| Normal-vs-Stage3 |
2.06719999999994E-05 |
| Normal-vs-Stage4 |
1.42140000003455E-06 |
| Stage1-vs-Stage2 |
7.425800E-02 |
| Stage1-vs-Stage3 |
1.387760E-01 |
| Stage1-vs-Stage4 |
6.641800E-01 |
| Stage2-vs-Stage3 |
1.752340E-02 |
| Stage2-vs-Stage4 |
2.727200E-01 |
| Stage3-vs-Stage4 |
1.354450E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.76879999536084E-08 |
| Normal-vs-AfricanAmerican |
3.849700E-04 |
| Normal-vs-Asian |
6.23339999950012E-07 |
| Caucasian-vs-AfricanAmerican |
8.480300E-02 |
| Caucasian-vs-Asian |
4.290000E-02 |
| AfricanAmerican-vs-Asian |
8.758600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.16870000343994E-08 |
| Normal-vs-Female |
2.9467994711041E-10 |
| Male-vs-Female |
7.249200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
6.83050005445551E-09 |
| Normal-vs-Age(41-60Yrs) |
1.26370000019804E-08 |
| Normal-vs-Age(61-80Yrs) |
7.94519999791632E-08 |
| Normal-vs-Age(81-100Yrs) |
1.076160E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.589000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.997000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.424800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.819800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.900400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.016800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.458890E-03 |
| Classical-VS-Follicular |
8.517800E-02 |
| Classical-VS-Other |
6.978400E-01 |
| Classical-VS-Normal |
1.51350043609E-10 |
| Tall-VS-Follicular |
1.431330E-04 |
| Tall-VS-Other |
2.890600E-01 |
| Tall-VS-Normal |
7.376000E-02 |
| Follicular-VS-Other |
9.595600E-01 |
| Follicular-VS-Normal |
7.09689973454886E-10 |
| Other-VS-Normal |
1.516390E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.7888024395063E-11 |
| Normal-vs-N1 |
3.679600E-03 |
| N0-vs-N1 |
9.478200E-02 |
|
|
